Anavex Life Sciences
Biotechnology, 630 5th Ave Fl 20, City, New York, 10111, United States, 11-50 Employees
Phone Number: 80********
Who is ANAVEX LIFE SCIENCES
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. The Companys...
Read More
-
Headquarters: 630 5th Ave Fl 20, New York City, New York, 10111, United States
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
CEO:
Christopher Missling
Email
Phone
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541711 |
Show More
Does something look wrong? Fix it. | View contact records from ANAVEX LIFE SCIENCES
Anavex Life Sciences Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Anavex Life Sciences
Answer: Anavex Life Sciences's headquarters are located at 630 5th Ave Fl 20, City, New York, 10111, United States
Answer: Anavex Life Sciences's phone number is 80********
Answer: Anavex Life Sciences's official website is https://anavex.com
Answer: Anavex Life Sciences's revenue is $1 Million to $5 Million
Answer: Anavex Life Sciences's SIC: 8731
Answer: Anavex Life Sciences's NAICS: 541711
Answer: Anavex Life Sciences has 11-50 employees
Answer: Anavex Life Sciences is in Biotechnology
Answer: Anavex Life Sciences contact info: Phone number: 80******** Website: https://anavex.com
Answer: Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. The Companys lead product candidate, ANAVEX2-73 is undergoing four mid- to late-stage clinical trial programs for CNS diseases where no good treatment options exist, or current treatments are inadequate. These include Alzheimers disease (Phase 2b/3) and Parkinsons disease dementia (Phase 2), which are neurodegenerative diseases that are on the rise due to aging populations in developed nations. Additionally, Anavex has two ongoing Phase 2 trials for Rett syndrome, a neurodevelopmental disease that mostly affects young female girls. Anavex has received Orphan Drug Designation from both the FDA and EMA for Rett syndrome. ANAVEX2-73 has potential to treat other CNS disorders, given its ability to restore upstream cellular homeostasis. Anavex has received funding from Rett Syndrome Foundation, as well as Michael J Fox Foundation supporting Anavexs studies. Anavex has identified a novel biomarker signature (genetic variants) that have potential to determine which patients will benefit the most from ANAVEX2-73, which targets the Sigma-1 receptor (SIGMAR1), a natural cell signaling pathway that is activated to restore cellular homeostasis.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month